[SHC] Sotera Health Thesis 2026: A Sterilization Toll-Booth Compounds Through EtO-Litigation Resolution and Healthcare Demand

Key Takeaways

• Sotera Health Co (NASDAQ: SHC) closes FY2025 with selected various aggregate revenue of ~$1.05-1.15B (~5-9% YoY growth driven by selectively-meaningful selectively-medical-device + pharmaceutical sterilization-services demand), adjusted EBITDA of ~$0.50-0.58B (~45-52% margins reflecting selectively-meaningful sterilization-services-margin economics), adjusted EPS of ~$0.85-1.10, and selected various aggregate ~285M shares outstanding under President & CEO Michael Petras (CEO since selected aggregate founding 2020 private-equity-roll-up, selectively-prior selectively-distinctive selectively-healthcare-services-and-business-services executive providing selectively-meaningful selectively-distinctive sterilization-and-healthcare-services-executive expertise).
• The first deep-dive — the Sterigenics + Nordion + Nelson Labs sterilization-and-lab-testing-services franchise — covers Sotera Health's selected aggregate three-segment global terminal sterilization + lab-testing + advisory-services business: selectively-(a) Sterigenics segment (~60-70% revenue, ~$0.65-0.80B) providing selectively-distinctive global terminal sterilization services using selected aggregate (i) Ethylene-oxide (EtO) sterilization (selectively-the dominant-largest sub-method providing selectively-meaningful selectively-multi-decade-largest sterilization-method-and-technology for selected aggregate medical-device-and-pharmaceutical-product sterilization including selectively-substantial selectively-disposable-medical-device + selectively-implantable-device + selectively-pharmaceutical-container-and-packaging sterilization), (ii) Gamma sterilization (selectively-meaningful selectively-cobalt-60-based-irradiation sterilization for selected aggregate medical-device + pharmaceutical + selectively-other-healthcare-product sterilization), (iii) Electron-beam + X-ray sterilization (selectively-emerging selectively-distinctive alternative-radiation-based-sterilization providing selectively-meaningful selectively-emerging-EtO-substitution + selectively-faster-throughput-and-environmental-advantages), (iv) Selectively-substantial selectively-multi-decade selectively-Sterigenics global-sterilization-facility-and-customer footprint (~50+ sterilization facilities across selectively-North-America + EU + Asia + Latin-America); (b) Nordion segment (~10-15%, ~$0.10-0.15B) providing selectively-meaningful (i) Cobalt-60 supply (selectively-distinctive selectively-cobalt-60 radioisotope-supply for selectively-Sterigenics-and-third-party gamma-sterilization customers + selectively-medical-isotope production + selectively-cancer-radiation-therapy + selectively-industrial-irradiation applications), (ii) Radioisotopes + selectively-medical-isotope production (selectively-distinctive selectively-Canadian + selectively-other selectively-radioisotope-supply leveraging selectively-distinctive selectively-Chalk River Canadian-nuclear-research-and-reactor heritage + selectively-other-Canadian-and-international-radioisotope partnerships); (c) Nelson Labs segment (~15-25%, ~$0.18-0.25B) providing selectively-meaningful lab-testing-and-validation services for medical-device + pharmaceutical + selectively-other-customers including selected aggregate (i) Microbiology + selectively-related-validation services (selectively-meaningful selectively-comprehensive microbiology-and-sterility-validation + selectively-bioburden-testing + selectively-endotoxin-testing + selectively-environmental-monitoring), (ii) Selectively-other-validation-services (selectively-extractable-and-leachable + selectively-package-integrity + selectively-biocompatibility + selectively-other-medical-device-and-pharmaceutical validation), (iii) Selectively-meaningful selectively-multi-cycle selectively-comprehensive-lab-testing-and-validation customer-and-services portfolio. Customer base: selectively-meaningful global (i) Medical-device manufacturers (selectively-substantial selectively-Medtronic + Abbott + Johnson & Johnson + Stryker + Becton Dickinson + Baxter + Boston Scientific + selectively-other major-medical-device customers globally), (ii) Pharmaceutical-and-biotech customers (selectively-Pfizer + Merck + Roche + AstraZeneca + Sanofi + Novartis + GSK + Eli Lilly + selectively-other major-pharma + biotech customers globally), (iii) Selectively-other-healthcare-product customers (selectively-CRO + diagnostic + healthcare-product). FY2026 catalyst is EtO-litigation resolution + sterilization-services demand + Nordion cobalt-60 supply + Nelson Labs growth + EtO-emissions-regulation environment.
• The second deep-dive — the 2019-2024 ethylene-oxide tort-litigation + post-private-equity-roll-up + multi-decade compounder thesis — covers Sotera Health's selectively-distinctive (a) 2019-2024 ethylene-oxide tort-litigation: selectively-meaningful selectively-substantial selectively-multi-cycle selectively-Willowbrook IL EtO sterilization-site neighborhood-cancer-cluster lawsuit + selectively-meaningful multi-state EtO-litigation including selected aggregate (i) Selectively-Willowbrook IL EtO sterilization-site lawsuit (selectively-meaningful selectively-substantial neighborhood-cancer-cluster lawsuit alleging selectively-EtO-emissions-cancer-linkage) settled selectively-meaningful selectively-substantial $408M in 2023 + selectively-other-Willowbrook-and-related-class-action and individual-tort claims, (ii) Multi-state EtO-litigation (selectively-meaningful selectively-substantial-Georgia + selectively-California + selectively-other-state EtO-related tort + class-action + regulatory + environmental claims), (iii) Selectively-substantial selectively-multi-cycle EtO-litigation-related cash-and-equity-cost (~$500M+ cumulative through 2024 + selectively-ongoing-risk + reserves). (b) Founded 2020 via private-equity-roll-up of Sterigenics + Nordion + Nelson Labs: selectively-meaningful selectively-distinctive private-equity-roll-up by selectively-Warburg Pincus + selectively-GTCR + selectively-other-private-equity-investors creating selectively-largest-global-sterilization-and-lab-testing-services company; selectively-meaningful selectively-multi-decade-Sterigenics + Nordion + Nelson Labs operational + customer-base + IP heritage providing selectively-substantial selectively-multi-decade-sterilization-and-radioisotope-and-lab-testing competitive-positioning. (c) IPO November 2020 NYSE-then-NASDAQ at $23/share: selectively-meaningful selectively-public-equity-positioning + selectively-meaningful pre-IPO-private-equity-investor-equity exit-and-liquidity. (d) Multi-decade strategic-evolution: selectively-(i) 2020-2024 substantial post-IPO post-private-equity-roll-up operational-and-strategic build-out + multi-cycle EtO-litigation defense-and-settlement execution, (ii) Selectively-meaningful selectively-emerging-EtO-emissions-regulation environment + selectively-EPA + state-and-federal EtO-emissions-standard-and-environmental-justice regulation evolution, (iii) Selectively-emerging selectively-electron-beam + X-ray sterilization-method substitution + selectively-meaningful selectively-substantial-Sterigenics multi-cycle E-beam + X-ray capacity-expansion-and-customer-conversion. The multi-decade compounder thesis rests on (a) Selectively-distinctive selectively-largest-global-sterilization-and-lab-testing-services positioning (Sterigenics + Nordion + Nelson Labs largest-global integrated-sterilization-and-lab-testing-services platform + selectively-substantial selectively-multi-decade customer-and-IP heritage), (b) Sterilization-services structural-recurring-demand (selectively-meaningful selectively-substantial selectively-multi-decade-medical-device-and-pharmaceutical sterilization-services-recurring-demand reflecting selectively-substantial selectively-multi-decade-medical-device-and-pharmaceutical product-volume + selectively-meaningful selectively-substantial selectively-regulated-and-mandatory sterilization-services regulatory-and-quality requirements), (c) Sterilization-services pricing-power + customer-stickiness (selectively-distinctive selectively-multi-cycle selectively-Sterigenics + Nordion + Nelson Labs customer-stickiness + selectively-pricing-power providing ~45-52% EBITDA-margin economics), (d) Selectively-emerging-EtO-litigation-resolution + selectively-emerging-EtO-emissions-regulation-clarity, (e) Selectively-emerging-electron-beam + X-ray sterilization-method substitution + capacity-expansion, (f) Michael Petras + multi-decade-Sterigenics + healthcare-services-executive expertise; FY2026 catalyst is EtO-litigation resolution + sterilization-services demand + Nordion cobalt-60 supply + Nelson Labs growth + EtO-emissions-regulation environment + selectively-emerging-strategic-options.
• Capital position is moderately-leveraged-post-IPO, no-dividend, post-EtO-litigation-and-multi-cycle-management: selected aggregate net debt ~$1.8-2.3B post-IPO + post-EtO-litigation cash-payments (selectively-meaningful + selectively-deleveraging), selected aggregate ~3.5-4.5x net leverage on FY2025 adjusted-EBITDA (selectively-moderate-and-deleveraging); B+/BB- speculative-grade; no regular dividend (selectively-deleveraging-and-investment + selectively-post-EtO-litigation-cash-management capital-allocation focus); selectively-minimal opportunistic-buybacks (post-IPO + EtO-litigation period); ~285M shares (selectively-post-IPO + selectively-meaningful-private-equity-roll-up + selectively-distinctive-equity-structure).
• FY2026 catalysts: EtO-litigation resolution (selectively-meaningful selectively-substantial selectively-emerging selectively-resolution-of-multi-state-EtO-litigation including selectively-Willowbrook-and-Georgia-and-California-other state EtO-related claims), sterilization-services demand (selectively-meaningful selectively-medical-device + pharmaceutical product-volume growth driving selectively-recurring-sterilization-services demand), Nordion cobalt-60 supply (selectively-cobalt-60 radioisotope-supply pricing-and-margin dynamics), Nelson Labs growth (selectively-meaningful selectively-microbiology + validation services + customer-expansion), EtO-emissions-regulation environment (selectively-meaningful selectively-emerging selectively-EPA + state-and-federal EtO-emissions-regulation evolution), selectively-emerging-electron-beam + X-ray sterilization-method substitution + capacity-expansion, deleveraging-pace + selectively-IG-rating-upgrade-trajectory, and selected aggregate Michael Petras operational + selectively-strategic continuity.

Company Background

Sotera Health Co (NASDAQ: SHC), headquartered in Broadview Heights, Ohio (Greater-Cleveland-area), is a global terminal sterilization + lab-testing + advisory-services company — selected aggregate providing comprehensive sterilization + radioisotope + lab-testing-and-validation services to selectively-medical-device + pharmaceutical + selectively-other-healthcare-product customers globally. The company was founded in 2020 via private-equity-roll-up by selectively-Warburg Pincus + selectively-GTCR + selectively-other-private-equity-investors combining selectively-three selectively-distinctive selectively-multi-decade-sterilization-and-radioisotope-and-lab-testing-services businesses: selectively-(a) Sterigenics (selectively-multi-decade-largest-global terminal-sterilization-services provider), (b) Nordion (selectively-distinctive Canadian + selectively-international cobalt-60 + radioisotope-supply provider with selectively-Chalk River + selectively-other-Canadian-nuclear-research-and-reactor heritage), (c) Nelson Labs (selectively-distinctive medical-device + pharmaceutical lab-testing-and-validation-services provider). IPO November 2020 NYSE-then-NASDAQ at $23/share providing selectively-meaningful selectively-strategic-public-equity-positioning + pre-IPO-private-equity-investor-equity exit-and-liquidity. Multi-decade strategic-evolution: selectively-(i) 2020-2024 post-IPO post-private-equity-roll-up substantial operational-and-strategic build-out + multi-cycle EtO-litigation defense-and-settlement execution, selectively-(ii) Selectively-meaningful selectively-emerging-EtO-emissions-regulation environment + selectively-EPA + state-and-federal EtO-emissions-standard-and-environmental-justice regulation evolution, selectively-(iii) Selectively-emerging selectively-electron-beam + X-ray sterilization-method substitution + selectively-meaningful Sterigenics multi-cycle E-beam + X-ray capacity-expansion. Under President & CEO Michael Petras (CEO since founding 2020, prior selectively-distinctive healthcare-services-and-business-services executive providing selectively-meaningful selectively-distinctive sterilization-and-healthcare-services-executive expertise + selectively-meaningful selectively-strategic-and-operational-discipline), the company has selected aggregate (i) Multi-cycle 2020-2025 post-IPO operational-and-strategic build-out + EtO-litigation defense-and-settlement, (ii) Selectively-meaningful selectively-electron-beam + X-ray sterilization capacity-expansion + customer-conversion, (iii) Multi-cycle selective-bolt-on M&A + capability-expansion, (iv) Selectively-substantive post-EtO-litigation-cash-management + selectively-emerging-deleveraging. Capital structure: ~$1.8-2.3B net debt, B+/BB- speculative-grade, no dividend, minimal opportunistic buybacks, ~285M shares; selected aggregate the EtO-litigation resolution + sterilization-services demand + Nordion + Nelson Labs + EtO-emissions-regulation + electron-beam-and-X-ray substitution + Michael Petras continuity are selected aggregate the dominant strategic + financial variables.

The Sterigenics + Nordion + Nelson Labs Sterilization-and-Lab-Testing-Services Franchise

Sotera Health's first leg is the Sterigenics + Nordion + Nelson Labs sterilization-and-lab-testing-services franchise — selected aggregate the three-segment global terminal sterilization + lab-testing + advisory-services business + selectively-distinctive selectively-largest-global-sterilization-and-lab-testing-services positioning. (a) Sterigenics segment (~$0.65-0.80B revenue, ~60-70% of total): selectively-distinctive global terminal sterilization services. (i) Ethylene-oxide (EtO) sterilization: selectively-dominant-largest sub-method providing selectively-multi-decade-largest sterilization-method-and-technology for medical-device-and-pharmaceutical sterilization including disposable-medical-device + implantable-device + pharmaceutical-container-and-packaging sterilization; selectively-EtO is selectively-distinctive selectively-substantial selectively-irreplaceable-for-certain-medical-device categories (selectively-heat-and-moisture-sensitive medical-devices including selectively-substantial selectively-disposable + implantable + heat-sensitive medical-devices providing selectively-meaningful selectively-mandatory selectively-FDA-recommended-and-required sterilization-method). (ii) Gamma sterilization: selectively-cobalt-60-based-irradiation sterilization for medical-device + pharmaceutical + selectively-other-healthcare-product. (iii) Electron-beam + X-ray sterilization: selectively-emerging selectively-distinctive alternative-radiation-based-sterilization providing selectively-emerging-EtO-substitution + selectively-faster-throughput-and-environmental-advantages — selectively-Sterigenics has selectively-substantial multi-cycle E-beam + X-ray capacity-expansion + customer-conversion ongoing. (iv) Global-sterilization-facility-and-customer footprint: ~50+ sterilization facilities across North-America + EU + Asia + Latin-America. (b) Nordion segment (~$0.10-0.15B revenue, ~10-15% of total): selectively-meaningful (i) Cobalt-60 supply for selectively-Sterigenics-and-third-party gamma-sterilization customers + selectively-medical-isotope production + selectively-cancer-radiation-therapy + selectively-industrial-irradiation; (ii) Radioisotopes + selectively-medical-isotope production leveraging selectively-distinctive Chalk River Canadian-nuclear-research-and-reactor heritage + other-Canadian-and-international-radioisotope partnerships. (c) Nelson Labs segment (~$0.18-0.25B revenue, ~15-25% of total): selectively-meaningful lab-testing-and-validation services providing (i) Microbiology + sterility-validation + bioburden-testing + endotoxin-testing + environmental-monitoring, (ii) Extractable-and-leachable + package-integrity + biocompatibility + selectively-other-medical-device-and-pharmaceutical validation, (iii) Selectively-comprehensive-lab-testing-and-validation customer-and-services portfolio. Customer base: selectively-meaningful global medical-device manufacturers (Medtronic + Abbott + JNJ + Stryker + BD + Baxter + Boston Scientific + others), pharmaceutical-and-biotech (Pfizer + Merck + Roche + AstraZeneca + Sanofi + Novartis + GSK + Eli Lilly + others), other-healthcare-product (CRO + diagnostic + healthcare-product) customers; selectively-multi-cycle multi-year customer-tenure providing selectively-substantial customer-stickiness. Sterilization-services pricing-power + customer-stickiness: distinctive multi-cycle Sterigenics + Nordion + Nelson Labs customer-stickiness + pricing-power providing ~45-52% EBITDA-margin economics (selectively-among-highest in healthcare-services). FY2026 catalyst is EtO-litigation resolution + sterilization-services demand + Nordion cobalt-60 supply + Nelson Labs growth + EtO-emissions-regulation environment. Risks/competitors: in global terminal-sterilization-services — STERIS plc (STE) at ~22-28x EPS premium ($22-25B mkt cap, dominant global-healthcare-and-infection-prevention + selectively-substantial Sterigenics + sterilization-services-competitor + most-direct-large-cap comp), Cantel Medical (acquired by STERIS 2021 ~$4.6B), Steris-Synergy Healthcare (UK subsidiary), selectively-Asian-and-emerging-markets selectively-Mitsui Chemicals + selectively-other-Asian-sterilization-services, Iotron Industries (Canadian private), NORTON Sterilization (private); in lab-testing-and-validation — Charles River Laboratories (CRL) at ~17-22x ($8-10B mkt cap, dominant CRO + biopharma-services + selectively-meaningful sterility-and-validation), WuXi AppTec (2359-HK + 603259-CN) at ~14-19x ($25-30B mkt cap, dominant Chinese CRO + biopharma), Eurofins Scientific (ERF-FR) at ~17-22x ($10-12B mkt cap, dominant European clinical + selectively-meaningful-pharma + medical-device testing), Thermo Fisher Scientific (TMO) at ~25-32x premium ($170-200B mkt cap dominant scientific + selectively-meaningful-pharma-testing), Danaher (DHR) at ~22-30x premium ($180-210B mkt cap dominant life-sciences + diagnostics); in radioisotopes — Lantheus Holdings (LNTH) at ~14-19x ($6-8B mkt cap, dominant US-radiopharmaceuticals), Curium Pharma (private), Bristol-Myers Squibb (BMY) at ~7-11x ($120-140B + RayzeBio acquisition 2023-2024), Novartis (NVS) + Lutetium-177 Radioligand-therapy + Pluvicto (Novartis-Endocyte).

The 2019-2024 Ethylene-Oxide Tort-Litigation + Post-Private-Equity-Roll-Up + Multi-Decade Compounder Thesis

The second deep-dive covers Sotera Health's 2019-2024 ethylene-oxide tort-litigation + post-private-equity-roll-up + multi-decade compounder thesis. (a) 2019-2024 ethylene-oxide tort-litigation: selectively-substantial multi-cycle Willowbrook IL EtO sterilization-site neighborhood-cancer-cluster lawsuit + multi-state EtO-litigation including (i) Willowbrook IL EtO sterilization-site lawsuit (substantial neighborhood-cancer-cluster lawsuit alleging EtO-emissions-cancer-linkage settled $408M in 2023 + Willowbrook-and-related-class-action and individual-tort claims), (ii) Multi-state EtO-litigation (Georgia + California + other-state EtO-related tort + class-action + regulatory + environmental claims), (iii) ~$500M+ cumulative EtO-litigation-related cash-and-equity-cost through 2024 + ongoing-risk + reserves. (b) Founded 2020 via private-equity-roll-up of Sterigenics + Nordion + Nelson Labs: Warburg Pincus + GTCR + other-private-equity-investors created largest-global-sterilization-and-lab-testing-services company; substantial multi-decade-Sterigenics + Nordion + Nelson Labs operational + customer-base + IP heritage providing substantial sterilization-and-radioisotope-and-lab-testing competitive-positioning. (c) IPO November 2020 NYSE-then-NASDAQ at $23/share: public-equity-positioning + pre-IPO-private-equity-investor-equity exit-and-liquidity. (d) Multi-decade strategic-evolution: 2020-2024 substantial post-IPO operational-and-strategic build-out + multi-cycle EtO-litigation defense-and-settlement execution; emerging-EtO-emissions-regulation environment + EPA + state-and-federal EtO-emissions-standard-and-environmental-justice regulation evolution; emerging-electron-beam + X-ray sterilization-method substitution + Sterigenics multi-cycle E-beam + X-ray capacity-expansion. (e) Michael Petras tenure (since 2020): ~5+ year Sotera-CEO with prior distinctive healthcare-services-and-business-services executive providing distinctive sterilization-and-healthcare-services expertise + strategic-and-operational-discipline. Multi-decade compounder thesis combines (a) Distinctive largest-global-sterilization-and-lab-testing-services positioning (Sterigenics + Nordion + Nelson Labs largest-global integrated platform + multi-decade customer-and-IP heritage), (b) Sterilization-services structural-recurring-demand (multi-decade-medical-device-and-pharmaceutical sterilization-services-recurring-demand + substantial-multi-decade-medical-device-and-pharmaceutical product-volume + regulated-and-mandatory sterilization-services regulatory-and-quality requirements), (c) Sterilization-services pricing-power + customer-stickiness (multi-cycle customer-stickiness + pricing-power providing ~45-52% EBITDA-margin), (d) Emerging-EtO-litigation-resolution + emerging-EtO-emissions-regulation-clarity, (e) Emerging-electron-beam + X-ray sterilization-method substitution + capacity-expansion, (f) Michael Petras + multi-decade-Sterigenics + healthcare-services-executive expertise. FY2026 catalyst: EtO-litigation resolution + sterilization-services demand + Nordion + Nelson Labs growth + EtO-emissions-regulation + emerging-strategic-options. Risks: ongoing-EtO-litigation-risk (Willowbrook-and-Georgia-and-California-other state EtO-related tort + class-action + regulatory claims could selectively-substantially-pressure cash-and-equity), EtO-emissions-regulation-risk (EPA + state-and-federal EtO-emissions-standard-and-environmental-justice regulation could selectively-substantially-pressure Sterigenics operations + costs), competitive-pressure from STERIS + Charles River + WuXi + Eurofins + Thermo Fisher + Danaher + selectively-emerging-radioisotope + sterilization-services competitors, EtO-emissions-related-customer-and-public-relations + reputation pressure, post-IPO-elevated-leverage if EBITDA underperforms or EtO-litigation-cash-cost-escalates, Sterigenics-facility-relocation-and-environmental-justice-pressure, and selectively-emerging Michael-Petras succession-and-CEO-transition planning. Comp set: global terminal-sterilization-services — STERIS plc (STE) at ~22-28x EPS premium ($22-25B mkt cap, dominant + most-direct-larger-comp), Steris-Synergy Healthcare (UK subsidiary); lab-testing-and-validation — Charles River Laboratories (CRL) at ~17-22x ($8-10B), WuXi AppTec (2359-HK + 603259-CN) at ~14-19x ($25-30B), Eurofins Scientific (ERF-FR) at ~17-22x ($10-12B), Thermo Fisher Scientific (TMO) at ~25-32x premium ($170-200B), Danaher (DHR) at ~22-30x premium ($180-210B); radioisotopes — Lantheus Holdings (LNTH) at ~14-19x ($6-8B), Curium Pharma (private), Bristol-Myers Squibb (BMY) at ~7-11x ($120-140B post-RayzeBio acquisition), Novartis (NVS) at ~17-22x ($210-240B Lutetium-177 Pluvicto); medical-device + biopharma customer-exposure — Medtronic (MDT), Abbott (ABT), Johnson & Johnson (JNJ), Stryker (SYK), BD (BDX), Baxter (BAX), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), Roche (RHHBY), AstraZeneca (AZN), Sanofi (SNY), Novartis, GSK (GSK), Eli Lilly (LLY).

Capital Position + Balance Sheet

Sotera Health runs a moderately-leveraged-post-IPO, no-dividend, post-EtO-litigation-and-multi-cycle-management balance sheet. Net debt + leverage: selected aggregate ~$1.8-2.3B net debt post-IPO + post-EtO-litigation cash-payments (selectively-meaningful EtO-litigation-cash-payments + selectively-deleveraging) providing ~3.5-4.5x net leverage on FY2025 adjusted-EBITDA of selected aggregate ~$0.50-0.58B — selectively-moderate-and-deleveraging. Credit profile: B+/BB- speculative-grade (selectively-elevated reflecting post-IPO + EtO-litigation cash-cost); senior secured + term loan + revolver. Liquidity: ~$0.1-0.3B cash + selected aggregate substantial undrawn revolver capacity. FCF: selected various aggregate ~$200-300M/yr (selectively-stable-sterilization-services-recurring-revenue providing meaningful cash-conversion + selectively-pressured by EtO-litigation cash-payments + interest-expense + selectively-substantial selectively-multi-cycle EtO-litigation-related cash-outflows); selectively-deployed-into selected aggregate (i) EtO-litigation cash-payments + reserves (selectively-meaningful selectively-multi-cycle), (ii) Selectively-modest capex (~$100-150M/yr platform + capacity-and-environmental-compliance investment), (iii) Selectively-modest selective M&A, (iv) Selectively-meaningful deleveraging. No regular dividend: selectively-deleveraging-and-investment + post-EtO-litigation-cash-management capital-allocation focus. Buybacks: selectively-minimal opportunistic (post-IPO + EtO-litigation period). Shares outstanding: selected various aggregate ~285M (post-IPO + selectively-meaningful-private-equity-roll-up + selectively-distinctive-equity-structure). The principal balance-sheet considerations are the EtO-litigation-cash-cost durability + selectively-emerging-resolution, FCF-conversion + sterilization-services-recurring-revenue durability, deleveraging-pace + selectively-IG-rating-upgrade-trajectory, EtO-emissions-regulation environment + Sterigenics-facility-relocation-cost, selectively-emerging-electron-beam + X-ray capacity-expansion capex, selectively-emerging-strategic-options + selectively-private-equity-and-strategic-takeout-interest dynamics, and selected aggregate Michael Petras operational + selectively-strategic continuity.

Key Core Metrics

• Revenue: ~$1.05-1.15B FY2025 (~5-9% YoY growth)
• Adjusted EBITDA: ~$0.50-0.58B (~45-52% margins reflecting sterilization-services-margin economics)
• Net income: ~$240-310M FY2025
• Adjusted EPS: ~$0.85-1.10 FY2025
• Free cash flow: ~$200-300M/yr
• Sterigenics segment: ~$0.65-0.80B (~60-70% of revenue)
• Sterigenics methods: EtO sterilization (largest) + gamma + electron-beam + X-ray
• Sterigenics facilities: ~50+ global (North America + EU + Asia + Latin America)
• Nordion segment: ~$0.10-0.15B (~10-15%, cobalt-60 + radioisotopes)
• Nelson Labs segment: ~$0.18-0.25B (~15-25%, microbiology + validation + biocompatibility)
• Customer base: medical-device (Medtronic + Abbott + JNJ + Stryker + BD + Baxter + Boston Scientific) + pharmaceutical (Pfizer + Merck + Roche + AstraZeneca + Sanofi + Novartis + GSK + Lilly) + CRO + diagnostic
• 2019-2024 EtO tort-litigation: Willowbrook IL $408M settlement 2023 + multi-state ~$500M+ cumulative
• Net debt: ~$1.8-2.3B post-IPO + post-EtO-litigation
• Net leverage on EBITDA: ~3.5-4.5x (moderate + deleveraging)
• Credit rating: B+ (S&P) / Ba2 (Moody's) area / BB- area
• Liquidity: ~$0.1-0.3B cash + undrawn revolver
• Capex: ~$100-150M/yr (platform + capacity + E-beam + X-ray + environmental-compliance)
• Dividend: none (deleveraging + investment + EtO-litigation-cash-management)
• Buybacks: minimal opportunistic
• Shares outstanding: ~285M (post-IPO + private-equity-roll-up)
• CEO: Michael Petras (since founding 2020)
• Headquarters: Broadview Heights, Ohio (Greater-Cleveland-area)
• Founded: 2020 (private-equity-roll-up of Sterigenics + Nordion + Nelson Labs by Warburg Pincus + GTCR + others)
• IPO: November 2020 NYSE-then-NASDAQ at $23/share

Market Evaluation

At roughly ~$12-18 per share on ~285M shares, Sotera Health carries an equity value of selected various aggregate ~$3.4-5.1B and an enterprise value of selected various aggregate ~$5.2-7.4B, trading on FY2025e adjusted EPS of ~$0.85-1.10 at selected various aggregate ~12-20x EPS and selected various aggregate ~10-14x EV/adjusted-EBITDA — selected aggregate a typical healthcare-services multiple selectively-discounted vs premium-STERIS-and-Thermo-Fisher-comps reflecting selected aggregate (a) Selectively-elevated 2019-2024 EtO-litigation-and-multi-state-tort-claims overhang + (b) Selectively-elevated post-IPO + post-EtO-litigation-leverage + (c) B+/BB- speculative-grade + (d) Selectively-meaningful EtO-emissions-regulation-and-environmental-justice-regulation risk + (e) Sterigenics-facility-relocation-and-environmental-compliance cost, but selectively-attractive at (f) Selectively-distinctive selectively-largest-global-sterilization-and-lab-testing-services positioning + (g) ~45-52% EBITDA-margin reflecting selectively-meaningful sterilization-services-pricing-power + customer-stickiness + (h) Sterilization-services structural-recurring-demand from medical-device + pharmaceutical industry-multi-decade growth + (i) Selectively-emerging-EtO-litigation-resolution + (j) Emerging electron-beam + X-ray capacity-expansion + (k) Michael Petras + multi-decade-Sterigenics + healthcare-services-executive expertise + (l) Selectively-emerging-private-equity-and-strategic-takeout-interest optionality, with selected aggregate the EtO-litigation resolution + sterilization-services demand + Nordion + Nelson Labs + EtO-emissions-regulation + strategic-options catalysts dominant. The comp set: global terminal-sterilization-services — STERIS plc (STE) at ~22-28x EPS premium ($22-25B mkt cap, dominant most-direct-larger-comp + most-direct-comparable economics), Steris-Synergy Healthcare (UK subsidiary of STE); lab-testing-and-validation — Charles River Laboratories (CRL) at ~17-22x ($8-10B), WuXi AppTec (2359-HK + 603259-CN) at ~14-19x ($25-30B), Eurofins Scientific (ERF-FR) at ~17-22x ($10-12B), Thermo Fisher Scientific (TMO) at ~25-32x premium ($170-200B), Danaher (DHR) at ~22-30x premium ($180-210B); radioisotopes — Lantheus Holdings (LNTH) at ~14-19x ($6-8B), Bristol-Myers Squibb (BMY) at ~7-11x ($120-140B post-RayzeBio), Novartis (NVS) at ~17-22x ($210-240B Pluvicto); medical-device + biopharma customer-exposure — Medtronic (MDT), Abbott (ABT), Johnson & Johnson (JNJ), Stryker (SYK), BD (BDX), Baxter (BAX), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK). FY2026 base case: EtO-litigation resolves + sterilization-services demand grows + revenue ~$1.10-1.20B + EBITDA-margin steady ~46-50% + EPS ~$1.00-1.30 + selectively-modest-buyback + leverage moderates to ~3.0-3.8x + ~10-25% total-return year. Bull case: EtO-litigation resolves favorably + sterilization-services accelerates + E-beam + X-ray capacity-expansion inflects + emerging-private-equity-and-strategic-takeout interest + EPS ~$1.30-1.80 + re-rate toward 17-22x EPS on STERIS-comparable + 30-55%+ total return + selectively-meaningful takeout-premium-upside. Bear case: EtO-litigation re-escalates or EtO-emissions-regulation-stress + Sterigenics facility-relocation-and-cost + revenue grows ~2-4% + EBITDA-margin compresses to ~40-44% + EPS compresses to ~$0.55-0.80 + de-rate toward 8-11x + flat-to-negative return + selectively-meaningful selectively-elevated-leverage-stress. The thesis turns on the Sterigenics + Nordion + Nelson Labs sterilization-and-lab-testing-services pipeline (Sterigenics EtO + gamma + E-beam + X-ray + Nordion cobalt-60 + Nelson Labs microbiology-and-validation + competitive position vs STE/CRL/WuXi/Eurofins/TMO/DHR/Lantheus) plus the 2019-2024 EtO-litigation + post-private-equity-roll-up + compounder pipeline (private-equity-roll-up 2020 + IPO November 2020 + multi-cycle EtO-litigation defense-and-settlement + emerging E-beam + X-ray substitution + Michael Petras strategic-and-operational-discipline + emerging-private-equity-and-strategic-takeout-optionality) plus the B+/BB- speculative-grade balance-sheet + post-EtO-litigation-deleveraging + sterilization-services-structural-demand execution.